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Abstract
Treatment of non small cell lung cancer (NSCLC) and colorectal cancer (CRC) have substantially changed in the last years
with the introduction of epidermal growth factor receptor (EGFR) inhibitors in the clinical practice. The understanding of
mechanisms which regulate cells sensitivity to these drugs is necessary for their optimal use. An in vitro model of acquired
resistance to two tyrosine kinase inhibitors (TKI) targeting the EGFR, erlotinib and gefitinib, and to a TKI targeting EGFR and
VEGFR, vandetanib, was developed by continuously treating the human NSCLC cell line CALU-3 and the human CRC cell line
HCT116 with escalating doses of each drug. MTT, western blot analysis, migration, invasion and anchorage-independent
colony forming assays were conducted in vitro and experiments with established xenografts in athymic nude mice were
performed in vivo in sensitive, wild type (WT) and TKI-resistant CALU-3 and HCT116 cell lines. As compared to WT CALU-3
and HCT116 human cancer cells, TKI-resistant cell lines showed a significant increase in the levels of activated,
phosphorylated AKT, MAPK, and of survivin. Considering the role of RAS and RAF as downstream signals of both the EGFR
and VEGFR pathways, we treated resistant cells with sorafenib, an inhibitor of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2,
VEGFR-3, and PDGFR-b. Sorafenib reduced the activation of MEK and MAPK and caused an inhibition of cell proliferation,
invasion, migration, anchorage-independent growth in vitro and of tumor growth in vivo of all TKI-resistant CALU-3 and
HCT116 cell lines. These data suggest that resistance to EGFR inhibitors is predominantly driven by the RAS/RAF/MAPK
pathway and can be overcame by treatment with sorafenib.
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Introduction
The epidermal growth factor receptor (EGFR) is a central
regulator of cancer cell proliferation and progression in several
human cancer types. The clinical efficacy of EGFR inhibitors
(cetuximab, panitumumab, erlotinib, gefitinib and vandetanib)
introduced in the clinical practice for the treatment of metastatic
cancers is limited to a subgroup of patients with the majority of
cancer patients showing either intrinsic or acquired resistance to
these drugs [1].
The recent progresses in the knowledge of cancer biology and
drug-resistance mechanisms have identified, among the intracel-
lular signalling pathways, that act as down-stream to the EGFR,
the AKT and RAS/RAF/ mitogen-activated protein kinase
(MAPK) pathways as major responsible for the development of
cancer cell resistance to EGFR inhibitors [2–4].
However, we recently demonstrated that, in our in vitro non
small cell lung cancer (NSCLC) model of acquired resistance to
erlotinib and gefitinib, treatment with several agents known to
target directly or indirectly the AKT signalling pathway, such ad
LY294002, deguelin and everolimus, was not efficacious in
inhibiting erlotinib- (ERL-) and gefitinib- (GEF-) resistant cancer
cell proliferation [5].
On the other side, mutations of the K-RAS gene has been
described both in NSCLC and colorectal cancer (CRC) patients as
responsible for a poor prognosis and poor response to EGFR
inhibitors [6]. These mutations cause KRAS proteins to
accumulate in the GTP-bound, active form leading to constitutive,
growth-factor-receptor independent activation of KRAS down-
stream signaling in tumor cells [7]. The development of
therapeutic strategies for patients with KRAS mutations is thus
an important clinical goal. RAF serine-threonine kinases are the
principal effectors of RAS in the MAPK signaling pathway and is
therefore a potential target for cancer therapy. To date, the most
successful clinical inhibitor of RAF activity is sorafenib (Nexavar,
BAY 43-9006) [8–10], an orally available multi-targeted kinase
inhibitor, that blocks the activation of C-RAF, B-RAF (both the
wild-type and the activated V600E mutant), c-KIT, FLT-3, RET,
vascular endothelial growth factor receptor 2 (VEGFR-2),
VEGFR-3, and platelet-derived growth factor receptor b
(PDGFR-b) [8–10], currently approved for the treatment of
metastatic renal cell carcinoma (RCC) and for advanced
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malignancies. Sorafenib affects tumor growth by directly inhibiting
tumor cell proliferation and promoting apoptosis in a variety of
tumor types as well as by inhibiting tumor-induced neoangiogen-
esis.
Our laboratory has recently provided evidence of a synergistic
interaction between sorafenib and erlotinib or between sorafenib
and cetuximab, a monoclonal antibody targeting the extracellular
domain of the EGF receptor, in a panel of NSCLC and colorectal
cancer (CRC) cell lines, in vitro and in vivo, which is accompanied
by a marked and sustained inhibition of the MAPK- and AKT-
dependent intracellular signals [11].
We hypothesized that treatment with sorafenib could overcome
the induced EGFR TKI-resistance by its ability to block several
growth factor receptor-driven signals. Moreover, because sorafe-
nib blocks B-RAF, and it could be effective in cancer cell lines
expressing activating K-RAS mutations.
In the present study, we report on the development and on the
characterization of human NSCLC and CRC cell lines with
acquired resistance to two tyrosine kinase inhibitors (TKI)
targeting the EGFR, erlotinib and gefitinib, and a TKI targeting
EGFR, VEGFR and RET, vandetanib, and on the antitumor
effects of sorafenib in these resistant cancer cell lines.
Results
Development and characterization of TKI-resistant
CALU-3 and HCT116 cancer cells
The human NSCLC CALU-3 cell line and the human CRC
HCT116 cell line harbour the wild type EGFR gene and an
activating K-RAS (KRASp.G13D) gene mutation. In contrast to
the other K-RAS mutations, this mutation has been described as
not influencing the sensitivity to anti-EGFR treatment, in
particular cetuximab [11]. These cancer cell lines has been
previously characterized by our group for the expression of the
four EGF-related growth factor receptors (EGFR, ERBB2,
ERBB3, and ERBB4) and of three VEGF receptors (VEGFR-
1,VEGFR-2, VEGFR-3), as well as for the expression of three
EGFR ligands (amphiregulin, EGF, and TGFa) and of three
VEGFR ligands (VEGF-A, VEGF-B, VEGF-C), by using
quantitative RT-PCR (qRT-PCR) [12]. All tested ligand mRNAs
were expressed in CALU-3 and HCT116 cell lines. CALU-3 cells
also expressed EGFR mRNA, whereas low levels of ERBB2 and
ERBB3 mRNAs were measurable. VEGFR-2 and VEGFR-3
mRNA expression was detected in CALU-3 cell line. Expression of
EGFR and its specific ligands suggests that in these human cancer
cell lines an EGFR-driven autocrine pathway is relevant for cancer
cell proliferation. In fact, CALU-3 and HCT116 cells are growth-
inhibited by treatment with selective EGFR TKIs, such as gefitinib
or erlotinib [13]. Furthermore, these cancer cells express both
VEGF ligands and VEGFRs and are growth inhibited by
treatment with anti-angiogenic TKIs [13].
Therefore, CALU-3 and HCT116 cells were selected as a
model for exploring the acquired resistance mechanisms to
treatment with the EGFR TKIs erlotinib and gefitinib, or with
the dual EGFR/VEGFR tyrosine kinase inhibitor vandetanib.
The gefitinib- (GEF-R), erlotinib- (ERL-R) and vadetanib-
(VAN-R) resistant cell lines were obtained by continuously
culturing CALU-3 and HCT116 cells in the presence of increasing
doses of each drug for 12 months. After the establishment of three
different TKI-resistant CALU-3 and three different TKI-resistant
CALU-3 HCT116 cell lines, we characterized their resistant
phenotype by doing cell proliferation assays in the presence of
each of these inhibitors. As illustrated in Table 1, an approxi-
mately 10-fold increase in the IC50 for each TKI-resistant cell line
as compared with parental cells was observed. ERL-R, GEF-R
and VAN-R CALU-3 and HCT116 human cancer cell lines were
cross-resistant to either gefitinib, erlotinib or vandetanib treat-
ment. We next confirmed the establishment of stable TKI-resistant
CALU-3 and HCT116 cancer cells in a drug-free culture medium.
In fact, all six TKI-resistant cell lines could grow in the absence of
each drug for long periods of time (three to six months) and
maintain their TKI-resistant phenotype (data not shown).
To further characterize the TKI-resistant CALU-3 and
HCT116 cell lines, we examined differential protein expression
among wild type, sensitive CALU-3 and HCT116 cells and their
TKI-resistant derivatives.
Activation of the EGFR leads to a complex intracellular
signalling which includes the activation of the pro-survival PI3K/
AKT pathway and the mitogenic RAS/RAF/MEK/MAPK
pathway [13,14]. We, therefore, investigated by immunoblotting
analysis these molecular pathways. As illustrated in Figure 1, EGF-
stimulated activation of the EGFR was efficiently blocked in WT
and ERL-R, GEF-R and VAN-R cells as demonstrated by the
inhibition of EGFR auto-phosporylation (P-EGFR).
Since the activated, phosphorylated forms of AKT and MAPK
are key intracellular mediators of growth factor-activated cell
survival and proliferation signals [13,14] investigating the
activation state of these molecular pathways may be of interest
in the understanding the resistance mechanisms. Activation of
MAPK and AKT with an increase in their phosphorylated forms
(P-MAPK and P-AKT) as well as an increase in survivin protein
levels were observed in all three TKI-resistant CALU-3 cell lines
and in all three TKI-resistant HCT116 cell lines as compared to
their parental counterpart (Figure 1).
Taken together, these results suggest that in this cancer cell
model of acquired resistance to three different TKIs, activation of
AKT- and MAPK-driven intracellular signals may be responsible
for cancer cell growth in the presence of either selective anti-
EGFR TKIs, such as gefitinib or erlotinib, or in the presence of
broad spectrum TKI, such as vandetanib.
Table 1. IC50 for treatment with erlotinib, gefitinib or vandetanib in parental CALU-3 and HCT116 cell lines (WT) and their TKI-
resistant derivatives (ERL-R, GEF-R, VAN-R).
CALU-3 HCT116
WT ERL-R GEF-R VAN-R WT ERL-R GEF-R VAN-R
ERLOTINIB 3 mM $25 mM $25 mM $25 mM7 mM $25 mM $25 mM $25 mM
GEFITINIB 6 mM $25 mM $25 mM $25 mM1 0 mM $25 mM $25 mM $25 mM
VANDETANIB 5 mM $25 mM $25 mM $25 mM6 mM $25 mM $25 mM $25 mM
doi:10.1371/journal.pone.0028841.t001
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In light of the role of RAS and RAF as downstream mediators
of both the EGFR and VEGFR signals from cell surface, we tested
the anti-proliferative effect of sorafenib, a multi-targeted kinase
inhibitor, blocking the activation of C-RAF, B-RAF, c-KIT, FLT-
3, RET, VEGFR-2, VEGFR-3, and PDGFR-b [8] on the parental
WT and TKI-resistant CALU-3 and HCT116 cancer cells. A
significant inhibition of cell growth was observed in both WT
CALU-3 cells and WT HCT116 cells and their corresponding
three TKI-resistant derivatives following sorafenib treatment, with
an IC50 ranging from 0. 1 to 0.5 mM, (Figure 2).We further
characterized the effects of sorafenib treatment on intracellular
signalling by Western blotting. As illustrated in Figure 3, treatment
of ERL-R, GEF-R and VAN-R CALU-3 and HCT116 cells with
sorafenib for 48 hours did not affect total MEK and MAPK
protein levels, while it caused a marked decrease of the
phosphorylated, activated forms of MEK (P-MEK) and of MAPK
(P-MAPK). Moreover, we investigated the activation status of all
molecular targets of sorafenib by studing the protein expression
levels of C-RAF, B-RAF, c-Kit, FLT-3, RET, VEGFR-2,
VEGFR-3 and PDGFRb, and their phosphoryation status by
western blotting analysis. Among all the targets of sorafenib
activity, only C-RAF and B-RAF resulted activated in resistant
CALU-3 and HCT116 cancer cell lines, and therefore strongly
inhibited by sorafenib treatment (Figure 3).
Effects of sorafenib treatment on the invasion, migration
and anchorage-independent growth of TKI-resistant
CALU-3 and HCT116 cancer cells
It has been suggested that cancer cells undergoing resistant to
anti-EGFR drugs could gain a more aggressive and metastatic
phenotype with increased ability to invade, migrate and to form
colonies in semisolid medium [15]. Therefore, we evaluated these
properties in TKI-sensitive WT CALU-3 and HCT116 cancer
cells and in their TKI-resistant derivatives. As illustrated in
Figure 4, WT CALU-3 and HCT116 cells demonstrated little or
no ability in invasion and migration. On the contrary, all TKI-
resistant CALU-3 and HCT116 cell lines exhibited significant
invasive and migratory abilities. Moreover, their anchorage-
independent colony growth was increased of approximately 3-fold
as compared to WT cells (Figure 4). Collectively, these results
suggest that cancer cell lines with acquired resistance to erlotinib,
gefitinib and vandetanib have acquired a more invasive and,
potentially, more metastatic behaviour.
We next evaluated the effects of sorafenib on the invasive and
migratory capabilities of the TKI-resistant CALU-3 and HCT116
cell lines. We did not tested the effect of sorafenib treatment on
TKI-sensitive WT cancer cell lines in consideration of the absence
of migratory and invasive ability. A significant dose-dependent
inhibition of invasion and migration was observed in all TKI-
resistant cell lines following treatment with sorafenib (Figure 4).
Effects of sorafenib on TKI-resistant CALU-3 and HCT116
tumor xenografts
We finally investigated the in vivo antitumor activity of
sorafenib in nude mice bearing WT CALU-3 and HCT116 or
TKI-resistant CALU-3 and HCT116 cell lines which were grown
subcutaneously as xenografts. In WT CALU-3 and HCT116
tumor xenografts, treatment with sorafenib caused a significant
decrease in tumor size as compared to control untreated mice. For
example, at day 35 from the starting of treatment, the mean tumor
volume in mice bearing WT tumor xenografts and treated with
sorafenib was respectively 38% and 31% in CALU-3 and
HCT116 as compared to control untreated mice (Figure 5, 6).
Also in mice bearing ERL-R, GEF-R or VAN-R CALU-3 and
HCT116 tumor xenografts, treatment with sorafenib induced a
significant reduction in tumor growth (Figure 5, 6). In this respect,
at day 35 from the starting of treatment, the mean tumor volumes
in the sorafenib-treated mice ranged between 27% and 40%, as
compared to control untreated mice.
Figure 1. Analysis of EGFR downstream pathways in parental CALU-3 and HCT116 cells (WT) and in their TKI-resistant derivatives
8ERL-R, GEF-R, VAN-R). Western blotting analysis of EGFR and of down-stream signalling pathways in parental human CALU-3 and HCT116 cells
(WT) and in their TKI-resistant derivatives (ERL-R, GEF-R, VAN-R). b-actin was included as a loading control.
doi:10.1371/journal.pone.0028841.g001
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Activation of the EGFR and the VEGFR pathways play a key
role in the development and progression of the majority of
epithelial cancers including NSCLC and CRC. However, only a
subgroup of patients benefits of treatments with drugs targeting the
EGFR or the VEGFR pathways [16]. Indeed, even in initially
responding patients secondary or acquired resistance occurs
causing cancer progression and treatment failure. Several
molecular mechanisms have been suggested to explain the
acquisition of cancer cell resistance to molecularly targeted anti-
cancer drugs [16].
Cancer cell resistance to EGFR antagonists could be due to
several reasons. Host related mechanisms, such as defective
immune-system activity, rapid metabolism or poor absorption,
are responsible for intrinsic or primary resistance. Moreover, the
genetic instability of these cells generates cancer cell clones with an
acquired resistance following prolonged exposure to EGFR
inhibitors. Since EGFR antagonists interfere with the activation
of several intracellular pathways that control cell proliferation,
Figure 2. Growth inhibitory effects of treatment with sorafenib in parental and TKI-resistant CALU-3 and HCT116 cancer cells. MTT
cell proliferation assays were performed in parental lung adenocarcinoma CALU-3 and colorectal cancer HCT116 cells. (WT) and in their TKI-resistant
derivatives (ERL-R, GEF-R, VAN-R ), treated for three days with the indicated concentrations of sorafenib. Results represent the average (6SD) of three
separate experiments, each performed in quadruplicate.
doi:10.1371/journal.pone.0028841.g002
Figure 3. Western blotting analysis of CALU-3 and HCT116 cells TKI-resistant derivatives (ERL-R, GEF-R, VAN-R) following
treatment with sorafenib. Western blotting analysis of C-RAF, B-RAF, MEK and MAPK activation following treatment with the indicated
concentration of sorafenib of lung adenocarcinoma CALU-3 and colorectal cancer HCT116 cells TKI-resistant derivatives (ERL-R, GEF-R, VAN-R ). b-actin
was included as a loading control.
doi:10.1371/journal.pone.0028841.g003
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induced angiogenesis, it is clear that several different molecular
changes could be responsible for the development of resistance to
these inhibitors [16].
In the present study, we found that cancer cells which develop
resistance to the EGFR tyrosine kinase inhibitors following long
time treatment (acquired resistance) exhibit activated RAS/RAF/
MAPK and AKT pathways. The EGFR-independent activation of
these downstream pathways makes cancer cells insensitive to the
EGFR inhibition and represents one of the most common
reported causes of resistance to EGFR-targeted therapy in solid
tumors.
The constitutive activity of at least one of these two pathways
has been demonstrated to be able to defines a resistant phenotype
unaffected by the treatment with gefitinib and cetuximab [2,17].
Persistent phosphorylation of the RAS/RAF/MAPK and/or AKT
pathways can be explained with the activation of cell surface receptors
o t h e rt h a nE G F Rs u c ha si n s u l i n - l i k eg r o w t hf a c t o r - 1r e c e p t o r( I G F -
1R) and MET [18–21], which are known to be iperexpressed or
activated in the presence of persistent inhibition of the EGFR.
Moreover, an increased receptor-independent activity of the
RAS/RAF/MAPK and/or AKT pathways could results from
direct gene amplification, activating/inactivating mutations or loss
of molecular regulator [22,23].
However, whereas inhibition of the AKT pathway does not
interfere with the proliferation of resistant cells, the inhibition of
the RAF/MEK/MAPK pathway by sorafenib treatment strongly
reduces cell growth and survival. Indeed, among all the molecular
targets of sorafenib, only C-RAF and B-RAF resulted activated in
resistant cell lines probably by upstream receptors not yet tested in
this work; however this information suggests that the activation of
RAF-dependent intracellular signals could be an important
mechanism in the acquisition of resistance to anti-EGFR therapy.
The RAS/RAF/MAPK signaling pathway is a promising
therapeutic target given its central role in regulation of
mammalian cell proliferation, relaying extracellular signals from
ligand-bound receptor tyrosine kinases at the cell surface to the
nucleus via a cascade of specific phosphorylation events. The
mutational status of RAS and B-RAF genes has been demon-
strated to affect the sensitivity of tumor cell lines to inhibitors of the
Figure 4. Effects of treatment with sorafenib on the invasive, migratory and anchorage-independent colony forming capabilities of
TKI-resistant CALU-3 and HCT116 cancer cells. Anchorage-independent growth (A), migration (B) and invasion (C), were evaluated in TKI-
resistant CALU-3 and HCT116 derivatives (ERL-R, GEF-R, VAN-R) after treatment with the indicated concentrations of sorafenib. The results are the
average 6 SD of three independent experiments, each done in triplicate. Representative pictures are shown for the migration and invasion abilities of
CALU-3 WT and Resistant cell lines.
doi:10.1371/journal.pone.0028841.g004
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has so far been unsuccessful. RAF serine-threonine kinases are the
principal effectors of RAS and are considered an important target
for cancer therapy. Agents such as sorafenib that bypass RAS and
inhibit effector molecules downstream of the mutant GTPase (e.g.
RAF) are being evaluated. Preclinical data have suggested that
sorafenib inhibits cell growth by inducing G1 arrest in NSCLC cell
lines independent of KRAS genotype [8].
Another possible mechanism of resistance to the EGFR
inhibition may be an increased angiogenic potential through
enhanced endothelial cell proliferation and permeabilization. On
the basis of this informations, several preclinical studies have been
realized with the intent to discover the effects of a combined
targeting of the erbB and VEGF pathways by using different
approaches [25–29]. In addition to the option of using anti- EGFR
therapies in combination with anti-VEGF drugs, a series of
tyrosine kinases that block both the EGFR and the VEGF receptor
TK were developed, such as vandetanib, which has demonstrated
significant activity as single agent and in combination with
traditional chemotherapeutics in several human tumor types [27–
29].
Often, EGFR inhibitor-resistant human cancer cell lines
exhibit, as common feature, VEGFR overexpression, increased
secretion of VEGF and placental growth factor, and augmented
migration capabilities. Sorafenib inhibits several RTKs that
participate in neovascularization, including vascular endothelial
growth factor receptor (VEGFR)-2 and VEGFR-3 [30]. Inhibition
of angiogenesis might thus be expected to contribute to the
inhibition of tumor growth by this drug in addition to its effects on
RAF signaling. Although sorafenib was previously shown to inhibit
the growth of a variety of human tumor xenografts in mice [8], it
has been difficult to measure the relative contributions of its
antiangiogenic activity and its direct antitumor activity mediated
by RAF inhibition. Moreover, in our work, the development of
human cancer cells resistant to vandetanib, excluded the possibility
that sorafenib’efficacy may depend on the inhibition of the
VEGFR.
Evidence of a positive interaction between sorafenib and anti-
EGFR drugs have recently been provided by our group [12].
Preclinical evidences supported a strong anti-proliferative and
anti-migratory effects in NSCLC and CRC cancer cell lines
following the combination with sorafenib plus ant-EGFR drugs
[12]. Moreover, a recent phase II clinical study supported the
combination of erlotinib and sorafenib in elderly patients with
advanced NSCLC in light of the higher 1-year survival rate [30].
In the present study, we have provided evidences that sorafenib
is active in inhibiting tumor cell growth in vitro and in vivo of human
cancer cells resistant to inhibitor of the EGFR and/or VEGFR.
The activity of sorafenib is strictly linked to its ability to block RAF
signaling through the RAS/RAF/MEK/MAPK pathway.
Methods
Cell lines, drugs and chemicals
The human NSCLC CALU-3 and the human CRC HCT116
cell lines were provided by the American Type Culture Collection
Figure 5. Antitumor activity of the sorafenib in parental and TKI-resistant CALU-3 xenografts. A, Parental (WT) CALU-3 cancer cells; B,
GEF-R CALU-3 cancer cells; C, VAN-R CALU-3cancer cells; D, ERL-R CALU-3 cancer cells. Athymic nude mice were injected subcutaneously into the
dorsal flank with 10
7 cancer cells. After 7 to 10 days (average tumor size, 75 mm
3), mice were treated as indicated in Materials and Methods for 5
weeks. Each treatment group consisted of 8 mice. Data represent the average (6SD). Student’s t test was used to compare tumor sizes among
different treatment groups at day 35 following the start of treatment. A, CALU-3 WT: sorafenib versus control (two-sided p,0.001); B, CALU-3 GEF-R:
sorafenib versus control (two-sided p,0.001). C, CALU-3 VAN-R: sorafenib versus control (two-sided p,0.001); D, CALU-3 ERL-R: sorafenib versus
control (two-sided p,0.001).
doi:10.1371/journal.pone.0028841.g005
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10% fetal bovine serum (FBS; Life Technologies, Gaithersburg,
MD) in a humidified atmosphere with 5% CO2. Gefitinib and
vandetanib were provided by AstraZeneca, Macclesfield, UK;
erlotinib was provided by Roche, Basel, Switzerland; sorafenib was
provided by Bayer Schering Pharma, Leverkusen, Germany.
Primary antibodies against P-EGFR (Tyr1173), EGFR, P-
MAPK44/42 (Thr202/Tyr204), MAPK44/42, P-AKT (Ser473),
AKT, P-MEK (Ser217/221), MEK, P-B-RAF (ser 445), P- C-RAF
(ser 338), survivin were obtained from Cell Signaling Technology,
Danvers, MA, USA. Cell invasion and migration assay kits were
obtained by Chemicon, Millipore, CA, USA. All other chemicals
were purchased from Sigma Aldrich, MO, USA.
Establishment of CALU-3 and HCT116 cancer cell lines
with acquired resistance to different TKIs
Over a period of 12 months, human CALU-3 lung adenocar-
cinoma cells and human HCT116 colorectal carcinoma cells were
continuously exposed to increasing concentrations of either
gefitinib, erlotinib or vandetanib, as previously described (12).
The starting dose was the dose causing the inhibition of 50% of
cancer cell growth (IC50) for each EGFR inhibitor (i.e.: erlotinib,
3 mM; gefitinib, 6 mM; vandetanib, 1 mM). The drug dose was
progressively increased to 15 mM in approximately two months, to
20 mM after other two months, to 25 mM after additional two
months, and, finally, to 30 mM for a total of 12 months. The
established resistant cancer cell lines were then maintained in
continuous culture with the maximally achieved dose of each TKI
that allowed cellular proliferation (30 mM for each drug).
Cell proliferation assay
Cancer cells were seeded in 96-well plates and were treated with
different drugs, such as erlotinib, gefitinib, vandetanib or sorafenib
for 72 hours. Cell proliferation was measured with the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say. The IC50 were determined by interpolation from the dose-
response curves. Results represents the median of three separate
experiments each performed in quadruplicate.
Western blotting analysis
Following treatment, cancer cells were lysed with Tween-20
lysis buffer (50 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl,
0.1% Tween-20, 10% glycerol, 2.5 mmol/L EGTA, 1 mmol/L
EDTA, 1 mmol/L DTT, 1 mmol/L phenylmethylsulfonylfluor-
ide, and 10 mg/mL of leupeptin and aprotinin) and sonicated.
Equal amounts of protein were analyzed by SDS-PAGE.
Thereafter, proteins were transferred to nitrocellulose membranes
and analyzed by specific primary antibodies, as indicated in the
experiment. Proteins were detected via incubation with horserad-
ish peroxidase–conjugated secondary antibodies and ECL chemi-
luminescence detection system.
Invasion assay
The invasive ability in vitro was measured by using transwell
chambers, according to the manufacturer’s protocol. Briefly, cells
were seeded onto the membrane of the upper chamber of the
transwell at a concentration of 2610
5/ml in 500 ml of RPMI
medium and were left untreated or treated with the indicated
doses of sorafenib for 24 hours. The medium in the upper
Figure 6. Antitumor activity of the sorafenib in parental and TKI-resistant HCT116 xenografts. A, Parental (WT) HCT116 cancer cells; B,
GEF-R HCT116 cancer cells; C, VAN-R HCT116 cancer cells; D, HCT116 cancer cells. Athymic nude mice were injected subcutaneously into the dorsal
flank with 10
7 cancer cells. After 7 to 10 days (average tumor size, 75 mm
3), mice were treated as indicated in Materials and Methods for 5 weeks.
Each treatment group consisted of 8 mice. Data represent the average (6SD). Student’s t test was used to compare tumor sizes among different
treatment groups at day 35 following the start of treatment. A, HCT116 WT: sorafenib versus control (two-sided p,0.001); B, HCT116: sorafenib versus
control (two-sided p,0.001). C, HCT116 VAN-R: sorafenib versus control (two-sided p,0.001); D, HCT116 ERL-R: sorafenib versus control (two-sided
p,0.001).
doi:10.1371/journal.pone.0028841.g006
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contained 10% FBS as a source of chemo-attractants. Cells that
passed through the Matrigel coated membrane were stained with
Cell Stain Solution containing crystal violet supplied in the
transwell invasion assay (Chemicon, Millipore, CA) and photo-
graphed after 20 hours of incubation. Absorbance was measured
at 562 nm by an ELISA reader after dissolving of stained cells in
10% acetic acid. Assays were performed in triplicate.
Migration assay
Cell migration was assessed using a commercially available
chemotaxis assay. Briefly, cells were incubated in RPMI serum-
free medium for 24 hand were left untreated or treated with the
indicated doses of sorafenib, following which they were detached
from flasks, suspended in quenching medium (serum-free medium
containing 5% bovine serum albumin) and EDTA, and seeded
into Boyden migration chamber inserts placed in a 24-well plate.
The inserts contain a microporous membrane with an 8-mm pore
size. Inserts were placed over wells containing serum-free media
plus chemo-attractant (10% FBS). After a 48-h treatment period,
cells/media were discarded from the top side of the migration
chamber insert and the chamber was placed in the wells of a new
24-well plate containing cell detachment solution. Following
incubation for 30 min at 37uC, the insert was discarded, and a
solution of lysis buffer and CyQuant GR dye was added to each
well. CyQuant is a green fluorescent dye that exhibits strong
enhancement of fluorescence when bound to cellular nucleic acids
released by the lysis buffer, enabling assessment of the relative
number of migrated cells. Fluorescence was determined with a
fluorimeter at 480/520 nm. Assays were performed in triplicate.
Growth in soft agar
Cells (10
4 cells/well) were suspended in 0.5 mL 0.3% Difco
Noble agar (Difco, Detroit, MI) supplemented with complete
culture medium. This suspension was layered over 0.5 mL 0.8%
agar-medium base layer in 24 multiwell cluster dishes (Becton
Dickinson, Lincoln Park, NJ) and treated with different concen-
trations of sorafenib. After 14 days, cells were stained with nitro
blue tetrazolium (Sigma, St. Louis, MO) and colonies larger than
0.05 mm were counted. Assays were performed in triplicate.
Tumor xenografts in nude mice
Four- to six-week old female balb/c athymic (nu+/nu+) mice
were purchased from Charles River Laboratories (Milan, Italy).
The research protocol was approved by the Second University of
Naples Animal Care and Use Committee (IT2010/20299). Mice
were maintained in accordance with the institutional guidelines of
the Second University of Naples Animal Care and Use
Committee. Mice were acclimatized for one week prior to being
injected with cancer cells and injected subcutaneously with 10
7
CALU-3 (WT, ERL-R, GEF-R, or VAN-R) cells or with 10
7
HCT116 (WT, ERL-R, GEF-R, or VAN-R) cells, that had been
resuspended in 200 mL of Matrigel (Becton Dickinson). When
established tumors of approximately 75 mm
3 in diameter were
detected, mice were treated with oral administrations of sorafenib
(50 mg/kg/day), for the indicated time periods. Each treatment
group consisted of 8 mice. Tumor volume was measured using the
formula p/6 x larger diameter x (smaller diameter)
2.
Statistical analysis
The Student’s t test was used to evaluate the statistical
significance of the results. All P values represent two-sided tests
of statistical significance. All analyses were performed with the
BMDP New System statistical package version 1.0for Microsoft
Windows (BMDP Statistical Software, Los Angeles, CA).
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